Cerevance Appoints David Lubner to Board of Directors
December 08 2020 - 10:17AM
Cerevance, a private drug discovery and development company focused
on brain diseases, today announced the appointment of David Lubner,
a senior finance executive with more than 25 years of experience in
the life sciences industry, to Cerevance’s Board of Directors.
Mr. Lubner most recently served as executive vice president and
chief financial officer of Ra Pharma, which was acquired by UCB in
April of this year. Before joining Ra Pharma, he served as a member
of the senior management team of Tetraphase Pharmaceuticals, Inc.
and PharMetrics Inc., a leading patient-based pharmacy and medical
claims data informatics company, and at ProScript, where Velcade®
(bortezomib), a therapy widely used for the treatment of multiple
myeloma, was discovered.
Mr. Lubner currently serves on the Board of Directors of Dyne
Therapeutics (Nasdaq: DYN), a company developing life-transforming
therapies for patients with serious muscle diseases, Therapeutics
Acquisition Corporation (Nasdaq: RACA), a blank check company
focused on the healthcare industry sponsored by RA Capital and
several other private biotechnology companies. He previously served
on the Board of Directors of Nightstar Therapeutics plc (Nasdaq:
NITE), a company focused on the development of one-time retinal
gene therapies for patients suffering from rare inherited retinal
diseases, which was acquired by Biogen in June 2019. Mr. Lubner is
a Certified Public Accountant. He received his B.S. in business
administration from Northeastern University and an M.S. in taxation
from Bentley University.
“David’s expertise across a wide range of financial, operational
and corporate strategic areas, in both senior management and Board
roles, will be a valuable complement to Cerevance’s Board,” said
Brad Margus, chief executive officer, co-founder and board member
of Cerevance. “We’re thrilled to gain his counsel as our company’s
powerful target discovery platform and rapidly expanding
therapeutic pipeline open new opportunities with partners and in
the capital markets.”
Mr. Lubner, stated, “I am pleased to be joining Cerevance’s
Board as the company works to advance novel treatments for a range
of neurodegenerative and psychiatric diseases for which effective
treatments are desperately needed. The company has assembled a
strong team of managers, advisors and investors, and I look forward
to contributing my expertise as we explore and execute on strategic
opportunities.”
About Cerevance
Cerevance, a private, clinical-stage pharmaceutical company
focused on brain diseases, is applying a new technology, called
NETSseq, to reveal transcriptional and epigenetic differences
between specific cell types in mature human brains. NETSseq
profiles neuronal and glial cell populations at depths not possible
with other approaches, generating unprecedented data sets and
insights. The company has thus far partnered with 19 brain banks
around the world to assemble a growing collection of more than
8,000 clinically annotated, human brain tissue samples from healthy
and diseased donors spanning nine decades in age. By applying
NETSseq to specific cell types critical to circuits disrupted by
disease and comparing vulnerable and resilient cell populations,
Cerevance’s scientists have begun identifying targets and advancing
a pipeline of novel therapeutics that modulate them for CNS
diseases.
Contacts
Cerevance:Robert Middlebrook,
+1-408-220-5722
Media:Andrew Mielach,
amielach@lifescicomms.com, +1-646-876-5868
Therapeutics Acquisition (NASDAQ:RACA)
Historical Stock Chart
From Sep 2024 to Oct 2024
Therapeutics Acquisition (NASDAQ:RACA)
Historical Stock Chart
From Oct 2023 to Oct 2024